Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Clinical trial NCT00281528 · TERMINATED

Trial details

NCT number: NCT00281528
Sponsor: Celgene
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Neoplasms Neoplasm Metastasis

Start date: 2006-02-01
Primary completion: 2010-07-01
Enrollment: 208

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.